Tarsus Pharmaceuticals, Inc.
TARS
Rangering i aksjer
#4590
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aksjekurs
$71.12
Sist synkronisert: 2026-10-20
Markedsverdi
$3.33B
Endring (1 dag)
2.33%
Endring (1 år)
0.42%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Antall utestående aksjer for Tarsus Pharmaceuticals, Inc. (TARS)
Antall utestående aksjer per June 2026: 43.39M
Ifølge Tarsus Pharmaceuticals, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 43.39M. Ved slutten av December 2023 hadde selskapet 29.38M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Tarsus Pharmaceuticals, Inc. (TARS) fra 2018 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 43.39M | 15.39% |
| 2024 | 37.60M | 27.98% |
| 2023 | 29.38M | 19.35% |
| 2022 | 24.62M | 19.78% |
| 2021 | 20.55M | 1.14% |
| 2020 | 20.32M | 4.17% |
| 2019 | 19.51M | 355.26% |
| 2018 | 4.29M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 485.11% |
US
|
|
| 396.00M | 812.58% |
US
|
|
| 478.91M | 1,003.65% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 43.31% |
NL
|
